BamSEC and AlphaSense Join Forces
Learn More

Alumis Inc.

NASDAQ: ALMS    
Share price (1/14/26): $24.34    
Market cap (1/14/26): $2.541 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 2 pages Alumis Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.9
from 10-K 2 pages Alumis Inc. Non-Employee Director Compensation Policy (As Amended and Restated on February 7, 2025) ​
12/34/56
EX-10.1
from 8-K 13 pages Alumis Inc. Severance and Change in Control Plan
12/34/56
EX-10.11
from 10-Q 6 pages Alumis, Inc. Incentive Compensation Recoupment Policy
12/34/56
EX-10.1
from 8-K 12 pages Common Stock Purchase Agreement
12/34/56
EX-10.10
from S-1/A 15 pages Alumis Inc. Indemnification Agreement
12/34/56
EX-10.9
from S-1/A 2 pages Alumis Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.8
from S-1/A 13 pages Alumis Inc. 2024 Employee Stock Purchase Plan Adopted by the Board of Directors: June 21, 2024 Approved by the Stockholders: June 23, 2024
12/34/56
EX-10.5
from S-1/A 7 pages Alumis Inc. Rsu Award Grant Notice
12/34/56
EX-10.4
from S-1/A 10 pages Alumis Inc. Stock Option Grant Notice
12/34/56
EX-10.3
from S-1/A 34 pages Alumis Inc. 2024 Equity Incentive Plan Adopted by the Board of Directors: June 21, 2024 Approved by the Stockholders: June 23, 2024
12/34/56
EX-10.22
from S-1 77 pages Stock Purchase Agreement Dated as of March 5, 2021 by and Among Fl2021-001, Inc., as Purchaser, Fronthera International Group Limited, as Seller and Fronthera U.S. Holdings, Inc., as the Company
12/34/56
EX-10.21
from S-1 16 pages This Is a Full-Time, Exempt Position, Carrying Considerable Responsibility and Is Integral to the Development and Success of the Business. We Are Excited About Your Interest in Joining the Company Full-Time. This Letter Agreement Formally Presents the Specifics of Our Contingent Offer for Your Consideration: Title: Chief Medical Officer Base Pay: $440,000.00 Per Year Status: Regular, Full-Time Employee, Exempt Reports To: Martin Babler, Chief Executive Officer Start Date: To Be Determined by Mutual Agreement Location: South San Francisco and Remote Scope and Location of Work
12/34/56
EX-10.20
from S-1 16 pages Title: Chief Financial Officer Base Pay: $400,000.00 Per Year Status: Regular, Full-Time Employee, Exempt Reports To: Martin Babler, Chief Executive Officer Start Date: March 30, 2022 Location: South San Francisco Scope of Work
12/34/56
EX-10.19
from S-1 17 pages Title: General Counsel Base Pay: $340,000 Per Year Status: Regular, Full-Time Employee, Exempt Reports To: Roy Hardiman Start Date: January 18, 2022 Location: South San Francisco / Remote Scope of Work
12/34/56
EX-10.18
from S-1 15 pages Esker Therapeutics, Inc. November 12, 2021
12/34/56
EX-10.17
from S-1 11 pages Amendment to Offer Letter
12/34/56
EX-10.16
from S-1 8 pages Re: Offer of Employment Title: Chief Development Officer Base Pay: $360,000.00 Per Year Status: Full-Time Employee, Exempt Reports To: June Lee Start Date: March 15, 2021 Scope of Work
12/34/56
EX-10.15
from S-1 16 pages Esker Therapeutics, Inc. September 15, 2021
12/34/56
EX-10.14
from S-1 16 pages Esker Therapeutics, Inc. September 15, 2021
12/34/56